CAGR Value :
The global microbial fermentation APIs market was valued at USD 27.23 billion in 2025 and is projected to reach USD 30.18 billion by 2032, at a CAGR of 1.5% during the forecast period.
Report Studies :
Microbial fermentation APIs (Active Pharmaceutical Ingredients) are complex molecules produced through the fermentation of microorganisms like bacteria, yeast, and fungi. These APIs are crucial components in a wide range of pharmaceutical drugs, including antibiotics (e.g., penicillins, cephalosporins), anticancer agents, immunosuppressants, and various biologics. The process involves the cultivation of microorganisms in large fermenters under controlled conditions to produce the desired compound, which is then extracted and purified for pharmaceutical use.
By Types :
Antibiotics
• Amino Acids
• Vitamins
• Nucleotides
• Organic Acids
• Hormones
• Biological Products
By Applications :
• Pharmaceutical & Biotechnology Companies
• Hospitals
• Research & Academic Laboratories
• Others
Key Industry Players
• Merck KGaA
• Ajinomoto Co., Inc.
• HGPF
• Huaxing Pharmaceutical
• North China Pharmaceutical Group (NCPC)
• Topfond Pharmaceutical
• DSM
• Tianyao Pharmaceutical
• CSPC Pharmaceutical Group
• Northeast Pharmaceutical Group
• Lukang Pharmaceutical
• Luwei Pharmaceutical
• Jiangshan (DSM)